Search
Oxogluric acid
go.drugbank.com/drugs/DB08845InvestigationalNutraceuticaland reduces nitrogen by combining with it as well. … Oxogluric acid is sold as a dietary supplement to athletes to improve their performance by helping to remove excess ammonia, but it is not officially approved for this indication and only experimental
Turoctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalAs such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients … hemophilia A [F3649].
Products: ESPEROCT 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, ESPEROCT 1000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETSelpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigationalSelpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … [A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers.
Synonyms: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileTriethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigationalTriethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. … [A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and
Categories: Compounds used in a research, industrial, or household settingBotulinum toxin type A
go.drugbank.com/drugs/DB00083ApprovedInvestigationalIn 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. … [A231824] With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other
Synonyms: BTX A, BTX-ACategories: Botulinum Toxins, Type ARamucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalRamucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. … By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation,
Categories: Vascular Endothelial Growth Factor Receptor 2 Antagonist, VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsHuman immunoglobulin G
go.drugbank.com/drugs/DB00028ApprovedInvestigationalIVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. … IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population.
Dolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalDolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. … This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Categories: Serotonin Receptor Antagonists, Serotonin 3 Receptor AntagonistsIcotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigationalIcotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.